Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,995,304
  • Shares Outstanding, K 260,467
  • Annual Sales, $ 4,163 M
  • Annual Income, $ 1,177 M
  • 60-Month Beta 0.88
  • Price/Sales 17.08
  • Price/Cash Flow 57.28
  • Price/Book 9.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 1.94
  • Number of Estimates 8
  • High Estimate 2.19
  • Low Estimate 1.79
  • Prior Year 0.97
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
261.30 +0.21%
on 08/11/20
304.00 -13.86%
on 07/20/20
-32.59 (-11.07%)
since 07/10/20
3-Month
254.41 +2.93%
on 05/27/20
306.08 -14.45%
on 07/07/20
-23.42 (-8.21%)
since 05/11/20
52-Week
165.23 +58.48%
on 10/02/19
306.08 -14.45%
on 07/07/20
+78.88 (+43.11%)
since 08/09/19

Most Recent Stories

More News
Look for Shares of Vertex Pharm to Potentially Rebound after Yesterday's 2.48% Sell Off

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $265.09 to a high of $272.29. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $268.58...

VRTX : 261.86 (-2.56%)
Vertex Pharm Falls 2.48% on Heavy Volume: Watch For Potential Rebound

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $265.09 to a high of $272.29. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $268.58...

VRTX : 261.86 (-2.56%)
Vertex Pharm Falls 1.28% on Heavy Volume: Watch For Potential Rebound

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $269.16 to a high of $273.88. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $271.16...

VRTX : 261.86 (-2.56%)
Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

AZN : 55.18 (-0.36%)
MRK : 80.91 (unch)
MRNA : 68.97 (-4.22%)
VRTX : 261.86 (-2.56%)
TOP 4 COVID Stocks to Buy Before a Vaccine is Created

As coronavirus cases continue to soar, the U.S. is in desperate need of a vaccine. Who will get there first? Here are four candidates to consider: AstraZeneca (AZN), Novavax (NVAX), Pfizer (PFE), and Moderna...

AZN : 55.18 (-0.36%)
NVAX : 149.48 (-16.26%)
PFE : 37.79 (-1.56%)
MRNA : 68.97 (-4.22%)
XPH : 43.72 (-1.93%)
VRTX : 261.86 (-2.56%)
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

BMRN : 116.83 (-1.20%)
MRNA : 68.97 (-4.22%)
VRTX : 261.86 (-2.56%)
CRSP : 89.45 (-1.45%)
Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

VRTX : 261.86 (-2.56%)
Vertex: 2Q Earnings Snapshot

BOSTON (AP) _ Vertex Pharmaceuticals Inc. (VRTX) on Thursday reported second-quarter profit of $837.3 million.

VRTX : 261.86 (-2.56%)
Vertex Reports Second-Quarter 2020 Financial Results

---Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion-

VRTX : 261.86 (-2.56%)
Top Stock Reports for AstraZeneca, Union Pacific & Altria

Top Stock Reports for AstraZeneca, Union Pacific & Altria

VRTX : 261.86 (-2.56%)
UNP : 190.35 (+1.87%)
UBER : 31.21 (-3.28%)
SAP : 159.15 (-0.31%)
MO : 43.60 (+0.88%)
AZN : 55.18 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 270.41
1st Resistance Point 266.13
Last Price 261.86
1st Support Level 259.44
2nd Support Level 257.03

See More

52-Week High 306.08
Last Price 261.86
Fibonacci 61.8% 252.28
Fibonacci 50% 235.65
Fibonacci 38.2% 219.03
52-Week Low 165.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar